Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes.
Chan EY, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Ma AL, Yamamura T, Sinha A, Bagga A, Hogan J, Dossier C, Vivarelli M, Liu ID, Kamei K, Ishikura K, Saini P, Tullus K.
Chan EY, et al. Among authors: bagga a.
Kidney Int. 2020 Feb;97(2):393-401. doi: 10.1016/j.kint.2019.09.033. Epub 2019 Oct 31.
Kidney Int. 2020.
PMID: 31874801
Free article.